We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

T Cells Recognize Recent SARS-CoV-2 Variants

By LabMedica International staff writers
Posted on 15 Apr 2021
Print article
Image: Immune T cells lymphocytes can seek and destroy a cell (green) infected with and making copies of SARS-CoV-2 (yellow) (Photo courtesy of US National Institute of Allergy and Infectious Diseases)
Image: Immune T cells lymphocytes can seek and destroy a cell (green) infected with and making copies of SARS-CoV-2 (yellow) (Photo courtesy of US National Institute of Allergy and Infectious Diseases)
Due to the proofreading ability of the coronavirus (CoV) RNA-dependent RNA polymerase, the evolution of the global SARS-CoV-2 viral population during the current pandemic has been relatively constrained as compared to other endemic RNA viruses that do not possess this ability.

During late 2020, three distinct variants that each possessed a significantly increased amount of amino acid polymorphisms were identified in association with spikes in cases of COVID-19 in the United Kingdom (variant B.1.1.7), South Africa (variant B.1.351), and Brazil (variant B.1.1.248). These variants all possess the N501Y mutation in the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, a primary target for neutralizing antibody (NAb) binding.

A collaborating team of scientists led by the Johns Hopkins University School of Medicine (Baltimore, MD, USA) analyzed blood cell samples from 30 people who had contracted and recovered from coronavirus disease 2019 (COVID-19) prior to the emergence of virus variants. Most (60%) individuals included in the analysis were male and samples were collected a median of 42.5 days (interquartile range, 37.5-48 days) from initial diagnosis. The team aimed to determine whether CD8+ T cells in the blood could still recognize the three main SARS-CoV-2 variants. Peripheral blood mononuclear cell (PBMC) samples from the patients were collected and examined across six different human leukocyte antigen (HLA) haplotypes (HLAA*01:01, HLA-A*02:01, HLA-A03:01, HLA-A*11:01, HLA-A*24:02 and HLA-B*07:02).

A multiplexed peptide-MHC tetramer staining approach permitted the screening of 408 potential SARS-CoV-2 candidate epitopes for CD8+ T cell recognition. T cells were also evaluated using a 28-marker phenotypic panel (Immunoscape Pte. Ltd, Singapore). A total of 52 unique epitope responses were found and were directed against several structural and non-structural viral proteins. For controls, CD8+ T cells were probed for reactivity for up to 20 different SARS-CoV-2-unrelated control peptides per HLA (Adenovirus-, CMV-, EBV-, Influenza-, and MART-1-derived epitopes).

The team reported that only one mutation found in the B.1.351-Spike overlapped with a previously identified epitope (1/52), suggesting that virtually all anti-SARS-CoV-2 CD8+ T-cell responses should recognize these newly described variants. This mutation is the D80A mutation in the Spike protein, and occurs in the third residue of the RFDN VLPF epitope. This is a HLA*A24:02-restricted epitope for which a CD8+ T cell response was detected in 1/5 HLA*A24:02+ individuals, and at a low frequency (0.005 of total CD8+ T-cells), indicating this is not a high-prevalence epitope.

The authors concluded that their data highlighted the potential significant role of a multi-epitope T cell response in limiting viral escape, and partly mediate protection from disease caused by the SARS-CoV-2 variants. It is important that vaccines used for widespread campaigns generate strong multivalent T-cell responses in addition to neutralizing antibody (Nab) and other humoral responses in order to optimize efficacy against the current SARS-CoV-2 and emerging strains. It will be important to continue to monitor the breadth, magnitude, and durability of the anti-SARS-CoV-2 T cell responses in recovered and vaccinated individuals as part of any assessment to determine if booster vaccinations are needed. The study was published on March 30, 2021 in the journal Open Forum Infectious Diseases.

Related Links:
Johns Hopkins University School of Medicine
Immunoscape Pte. Ltd


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.